Iris Rajman new board member of CTR
Iris Rajman MD, PhD has been apponted as a new board member of Center for Translational Research (CTR).

Iris is a pharmaceutical industry executive with extensive senior leadership experience across global pharma companies. She brings deep expertise in translational medicine and portfolio governance, and has chaired several high-impact committees while overseeing more than a hundred regulatory registrations.

Her international experience, strategic insight, and strong industry network—combined with a proven track record of scaling organizations—will be invaluable as CTR continues the growth journey and expanding the international footprint.

At a time when the demand for high-quality R&D support is rapidly increasing, Iris expertise will help guide the strategic direction, support sustainable growth, and further strengthen how CTR will deliver value to both current and future customers.

Gå tillbaka